Matthew Krummel


Matthew F. Krummel '' is a Professor in the Pathology Department at University of California, San Francisco. He is known for systems immunology and studies mechanisms that regulate the immune system.

Career

Krummel holds the Robert E. Smith Endowed Chair in Pathology and is the co-founder and inaugural Chair of the UCSF ImmunoX Initiative. His lab uses real-time imaging and high-dimensional cytometry and sequencing to launch and test hypotheses related to how the immune system processes information and makes decisions. His recent discoveries include determining features of T cell membrane biology and how the movement of immune cells governs their ability to efficiently survey for antigens. Additionally, his research has revealed archetypal collections of immune systems in cancer, namely those involving networks of cells built around stimulatory dendritic cells.
Krummel developed a novel industry consortium-funded project that unites studies of cancer indications to understand the biology of individual patients and founded a microscopy ‘collaboratory’ at UCSF. He also founded the ImmunoX initiative, together with other UCSF faculty, which is a radical collaboration platform focused on methods and data sharing as a means to accelerate discovery and cures.
Krummel founded Pionyr Immunotherapeutics where he discovered new next-generation immunotherapeutics targeting myeloid cells.He co-founded Foundery Innovations, a novel biotechnology venture fund and studio that translates early-stage drug concepts through extensive academic-industry collaborations, most recently with the University of California, San Francisco, and the University of Arizona. In the lab of James P. Allison at UC Berkeley, Krummel conducted key studies on the function of the protein CTLA-4; together they developed and described the first CTLA-4 inhibitors. They subsequently collaborated to apply the same inhibitors in tumor models, providing data on the blockade of inhibitory receptors can augment tumor immune responses, the basis for the 2018 Nobel Prize in Medicine and Physiology as well as the first patents for anti-CTLA-4 checkpoint blockade.
Krummel received his Ph.D. at the University of California, Berkeley, and completed his postdoctoral studies at Stanford University.

Honors